Selective MT2 Agonist Composition for Pain and Sleep Disorders
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current melatonin receptor modulators, such as Ramelteon and Agomelatine, are non-selective, leading to limited bioavailability and pharmacological efficacy due to extensive first-pass metabolism, and they target both MT1 and MT2 receptors with opposing effects, which limits their therapeutic use.
Innovation Solution
Development of a selective MT2 receptor partial agonist, UCM924, which is a compound of formula (I) or its pharmaceutically acceptable salts, designed to manage or treat diseases associated with MT2 receptor activity, including chronic and acute pain, anxiety, and sleep disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-selective MT1/MT2 receptor agonists (e.g., Ramelteon, Agomelatine) are used, then both receptor subtypes are activated, but bioavailability is limited and pharmacological efficacy is reduced due to extensive first-pass metabolism
Solution Approach 1:
The patent modifies the chemical structure of melatonin receptor ligands by changing molecular parameters (introducing specific substituents at positions R1-R6 in formula I) to achieve selective MT2 receptor activation while improving oral bioavailability. The structural modifications include adding hydrophilic groups and adjusting molecular weight to optimize absorption and reduce first-pass metabolism.
Solution Approach 2:
The patent achieves local selectivity by designing compounds that preferentially bind to MT2 receptors over MT1 receptors through specific structural features at defined positions (R1-R6). This local quality differentiation allows selective activation of MT2 receptors in specific tissues (brain, peripheral nervous system) while avoiding non-selective effects.
2Adaptability or versatility
If non-selective MT1/MT2 receptor agonists are used, then both receptors are targeted, but therapeutic use is limited due to opposing effects of the two receptor subtypes
Solution Approach 1:
The patent segments the melatonin receptor system by developing selective MT2 agonists that isolate the therapeutic effects of MT2 activation from MT1 effects. This segmentation allows independent optimization of MT2-specific therapies for conditions like insomnia, anxiety, and pain, without the confounding opposite effects of MT1 activation.
Solution Approach 2:
The patent applies local quality by creating receptor-selective ligands with specific molecular features (substituents at R1-R6 positions) that confer preferential binding to MT2 receptors. This enables localized therapeutic action at MT2 receptors in specific brain regions and peripheral tissues, achieving condition-specific efficacy.
3Reliability
If selective MT2 receptor agonists are developed, then receptor selectivity is improved, but oral bioavailability remains limited due to first-pass metabolism
Solution Approach 1:
The patent changes molecular parameters of the selective MT2 agonist compounds (formula I) to optimize oral bioavailability. Specific modifications include adding hydrophilic substituents at R2 and R6 positions, adjusting molecular weight and lipophilicity balance, and modifying metabolic stability to reduce first-pass metabolism while maintaining receptor selectivity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
UCM924 demonstrates potent antinociceptive properties without motor impairments and effectively manages chronic neuropathic pain, anxiety, and sleep disorders by selectively activating MT2 receptors, enhancing pharmacological effects and avoiding receptor desensitization.
Implementation Method 1
UCM924 demonstrates potent antinociceptive properties without motor impairments and effectively manages chronic neuropathic pain, anxiety, and sleep disorders by selectively activating MT2 receptors
Data Source
AI summary
There is provided compounds of formula (I) or a pharmaceutically acceptable salt thereof, which are melatonin MT2 agonists, as well as pharmaceutical compositions comprising such compounds. The invention also provides the use of the compounds and pharmaceutically acceptable salts thereof described herein (or pharmaceutical compositions comprising same) for managing or treating a disease, disorder or condition associated with melatonin receptor activity such as pain, neuropsychiatric disorders, sleep, chronobiological and circadian rhythm disorders, hyperthermia, and metabolic disorders. (I).